Hua Medicine (Shanghai) Ltd
Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination w… Read more
Hua Medicine (Shanghai) Ltd (HUMDF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.080x
Based on the latest financial reports, Hua Medicine (Shanghai) Ltd (HUMDF) has a cash flow conversion efficiency ratio of -0.080x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-84.41 Million) by net assets ($1.06 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hua Medicine (Shanghai) Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Hua Medicine (Shanghai) Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hua Medicine (Shanghai) Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hua Medicine (Shanghai) Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
True North Commercial Real Estate Investment Trust
PINK:TUERF
|
0.042x |
|
Sinar Mas Multiartha Tbk
JK:SMMA
|
0.075x |
|
Graphite One Inc
OTCQX:GPHOF
|
-0.031x |
|
RattanIndia Enterprises Limited
NSE:RTNINDIA
|
0.010x |
|
Chant Sincere Co Ltd
TW:6205
|
0.022x |
|
Acer E-Enabling Service Business Inc.
TWO:6811
|
0.397x |
|
Maywood Acquisition Corp. Unit
NASDAQ:MAYAU
|
-0.002x |
|
Digimarc Corporation
NASDAQ:DMRC
|
-0.063x |
Annual Cash Flow Conversion Efficiency for Hua Medicine (Shanghai) Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Hua Medicine (Shanghai) Ltd from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-135.47 Million | $-417.97 Million | 3.085x | -64.91% |
| 2023-12-31 | $101.15 Million | $889.37 Million | 8.792x | +1168.25% |
| 2022-12-31 | $279.58 Million | $-230.11 Million | -0.823x | -35.78% |
| 2021-12-31 | $450.33 Million | $-272.98 Million | -0.606x | -2023.90% |
| 2020-12-31 | $732.50 Million | $-20.91 Million | -0.029x | +91.15% |
| 2019-12-31 | $1.06 Billion | $-342.07 Million | -0.323x | -68.01% |
| 2018-12-31 | $1.40 Billion | $-269.42 Million | -0.192x | -191.06% |
| 2017-12-31 | $-942.53 Million | $-198.69 Million | 0.211x | +84.67% |
| 2016-12-31 | $-666.20 Million | $-76.05 Million | 0.114x | -- |